These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17261781)

  • 1. Implications for estrogens in Parkinson's disease: an epidemiological approach.
    Ragonese P; D'Amelio M; Savettieri G
    Ann N Y Acad Sci; 2006 Nov; 1089():373-82. PubMed ID: 17261781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
    Morissette M; Al Sweidi S; Callier S; Di Paolo T
    Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
    Dluzen DE; McDermott JL
    J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective actions of sex steroids in Parkinson's disease.
    Bourque M; Dluzen DE; Di Paolo T
    Front Neuroendocrinol; 2009 Jul; 30(2):142-57. PubMed ID: 19410597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paraquat and Parkinson's disease.
    Berry C; La Vecchia C; Nicotera P
    Cell Death Differ; 2010 Jul; 17(7):1115-25. PubMed ID: 20094060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.
    Gillies GE; Murray HE; Dexter D; McArthur S
    Pharmacol Biochem Behav; 2004 Jul; 78(3):513-22. PubMed ID: 15251260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproductive factors and Parkinson's disease: a multicenter case-control study.
    Nicoletti A; Nicoletti G; Arabia G; Annesi G; De Mari M; Lamberti P; Grasso L; Marconi R; Epifanio A; Morgante L; Cozzolino A; Barone P; Quattrone A; Zappia M
    Mov Disord; 2011 Dec; 26(14):2563-6. PubMed ID: 21956541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age at menopause predicts age at onset of Parkinson's disease.
    Ragonese P; D'Amelio M; Callari G; Salemi G; Morgante L; Savettieri G
    Mov Disord; 2006 Dec; 21(12):2211-4. PubMed ID: 17029261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
    Morale MC; L'Episcopo F; Tirolo C; Giaquinta G; Caniglia S; Testa N; Arcieri P; Serra PA; Lupo G; Alberghina M; Harada N; Honda S; Panzica GC; Marchetti B
    Brain Res Rev; 2008 Mar; 57(2):431-43. PubMed ID: 18063054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and reproductive life events.
    Martignoni E; Nappi RE; Citterio A; Calandrella D; Corengia E; Fignon A; Zangaglia R; Riboldazzi G; Pacchetti C; Nappi G
    Neurol Sci; 2002 Sep; 23 Suppl 2():S85-6. PubMed ID: 12548356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender disparities in Parkinson's disease.
    Shulman LM; Bhat V
    Expert Rev Neurother; 2006 Mar; 6(3):407-16. PubMed ID: 16533144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case control study of women with Parkinson's disease and their fertility characteristics.
    Yadav R; Shukla G; Goyal V; Singh S; Behari M
    J Neurol Sci; 2012 Aug; 319(1-2):135-8. PubMed ID: 22647587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive factors and clinical features of Parkinson's disease.
    Cereda E; Barichella M; Cassani E; Caccialanza R; Pezzoli G
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1094-9. PubMed ID: 23931933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
    Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
    Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiologic studies of environmental exposures in Parkinson's disease.
    Elbaz A; Tranchant C
    J Neurol Sci; 2007 Nov; 262(1-2):37-44. PubMed ID: 17673256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen and movement disorders.
    Kompoliti K
    Clin Neuropharmacol; 1999; 22(6):318-26. PubMed ID: 10626091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease and cancer: insights for pathogenesis from epidemiology .
    D'Amelio M; Ragonese P; Sconzo G; Aridon P; Savettieri G
    Ann N Y Acad Sci; 2009 Feb; 1155():324-34. PubMed ID: 19250224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset.
    Giladi N; Weitzman N; Schreiber S; Shabtai H; Peretz C
    J Psychopharmacol; 2007 Jul; 21(5):501-6. PubMed ID: 17446202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.